Matt Kaeberlein discusses the potential impact of Rapamycin on glucose tolerance and suggests that the observed changes may actually reflect a different physiological state rather than a defect. He highlights the profound effects of Rapamycin on fat metabolism and ketogenesis, suggesting that these adaptations could contribute to the beneficial effects of the drug.
